No new safety signals were reported with the androgen receptor pathway inhibitor.
Danielle Ternyila
Advertisement
Articles by Danielle Ternyila
Advertisement
Latest Updated Articles
Subgroup data sustain enzalutamide PFS benefit in nmCRPCPublished: December 7th 2020 | Updated:
Advertisement
Advertisement
Trending on Urology Times
1
CORE-008: Cretostimogene achieves high CR rate in high-risk NMIBC
2
Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC
3
Choosing salvage therapy after prostate cancer focal ablation
4
SYNC-T demonstrates high bone metastasis resolution in phase 1 cohort
5
